Share

cover art for From Science Journalist to STEM Media Entrepreneur: unleash your big vision with Heather Catchpole STEM entrepreneurship journey - Refraction Media Transforming STEM Storytelling

Multiple hats

From Science Journalist to STEM Media Entrepreneur: unleash your big vision with Heather Catchpole STEM entrepreneurship journey - Refraction Media Transforming STEM Storytelling

Ep. 1
•

🎙️ From Science Journalist to STEM Media Entrepreneur: How Heather Catchpole Co-Founded Refraction Media to Transform STEM Storytelling

After a decade in science journalism, Heather Catchpole co-founded Refraction Media—now publishing 2 million magazines globally—proving there’s a scalable, sustainable business in making STEM visible, visual, and inspiring ( and recognized by Barack Obama for their impact).


🔍 What You’ll Learn:

  • How to directly transfer your work experience into your own business
  • How to be unapologetically ambitious ( and pull it off)
  • Why knowing your audience inside out is the secret sauce to scaling sustainably
  • Overcome the detractors
  • How strategic partnerships (like Google) can take your startup global in under two years
  • How to choose your growth model to fit the life you want



🧠 About the Guest:

Heather Catchpole is the co-founder of Refraction Media, an award-winning science media company creating high-impact STEM content for students, governments, and global tech companies. With a background in geoscience, a Master’s in science communication, and experience at CSIRO, ABC, and the Powerhouse Museum, Heather has built a powerhouse brand now delivering 2 million magazines a year and supporting 75,000 digital users per month.


📌 Episode Highlights:

00:00 Geoscience beginnings and discovering the joy of storytelling

04:00 Why she left the lab for a Master’s in Science Communication

07:00 ABC, CSIRO, and editing national journals as a freelance science writer

10:00 Career pivots, parenthood, and wearing “multiple hats” in media

12:00 How to tell science stories in ways that make people care

14:00 Founding Refraction Media: the story behind the name and mission

16:00 From virtual nuclear reactors to national school programs

18:00 Co-founding with Karen Taylor-Brown over a pub lunch

20:00 Bootstrapping, business modelling, and cash flow basics

22:00 The Google connection—and getting listed by Barack Obama

24:00 Why diverse teams matter in tech and science content

26:00 Growing fast vs. growing sustainably—and making the right choice

30:00 Hiring, managing, and why co-founding with the right person matters

33:00 Staying profitable, going global, and the power of reputation

35:00 Strategic mindset, managing risk, and trusting your gut

40:00 Burnout and resilience: how to recognize and manage both

44:00 Kids, guilt, and building a professional identity alongside parenthood

46:00 On privilege, imposter syndrome, and redefining success as a woman in STEMM

49:00 Gender gaps in STEM and how inclusive storytelling changes outcomes

51:00 Final reflections: team science, happy businesses, and brave leaps


🔗 Resources Mentioned:


🤔 Reflection Time:

  • What’s your version of a “pub lunch idea”—a business that combines what you know with what the world needs?
  • Are you clear on your audience? Could knowing them better be the key to growth or reinvention?
  • What kind of business do you want to lead—a startup for scale or a sustainable niche you can love long-term?



ďťżWant to craft a career story that opens doors?

I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you.

📬 Let’s connect: angeliquegreco.com.au | LinkedIn 


 

⭐️ Help More People Reinvent Their Careers

If you enjoyed this episode, please:

  • ✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify 🙏
  • ♻️ Share it with a friend who's questioning their path in STEM

More episodes

View all episodes

  • 44. STEM Careers Beyond the Job Description, How to Own Your Path and When to Build Your Own Box, with STEM founder Catherine O’Mahony

    59:04||Ep. 44
    You are a STEM professional and you tick every box on paper, so why do you still feel boxed in, underused, or quietly restless at work?🔍 What You’ll Learn:If you are a STEM professional who has done everything right but feels stuck in a narrow lane, this episode is for you.We unpack the dynamics shaping recruitment and job seeking and how you can find breadth beyond the job description and when to build your own box with insights from Catherine's own founder journey.You will learn:What actually makes a STEM candidate stand out beyond the job description, and why EQ, delivery, and motivation matter more than endless upskillingWhy most companies hire you to stay in your lane, and how to deliberately create breadth without burning trust or credibilityHow to take ownership of your career, whether that is shaping a role internally, choosing the right company size, or stepping into entrepreneurshipHit play if you want practical, grounded advice on how to design a STEM career that fits your life, not just your CV.This episode was recorded in July 2025 but Catherine's word are as relevant today as they were a few months back. 🧠 About the Guest:Catherine O’Mahony is the CEO and founder of OnQ Recruitment, which she started 25 years ago. With a background in science and decades of experience placing talent across the life sciences, Catherine brings a rare dual perspective, how careers are built inside organisations, and how creating your own business can be a deliberate career move rather than a leap into chaos.📌 Episode Highlights:00:00 Why high-performing STEM professionals still feel underused03:45 How STEM recruitment has changed since 1999, from fax machines to LinkedIn07:00 What makes a stellar candidate beyond technical skills10:41 Learning fast vs delivering value, where many STEM professionals trip up15:00 Employer value proposition, power shifts after COVID, and what changed back22:00 Salary transparency, equity, and what the data really shows in life sciences27:40 Why women are still underrepresented at the top, and the role of advocates32:10 Beyond the job description, breadth vs depth and choosing the right company size38:00 Why career ownership is not your manager’s job45:00 Catherine’s founder story, the real first step to starting a business52:00 Rapid-fire truths on transferable skills, perfectionism, and taking action🔗 Resources Mentioned:OnQ Recruitment Salary Survey – https://www.onqrecruitment.com.auCompany Directors Course (AICD) – https://aicd.com.au🤔 Reflection Time:Where in your current role are you delivering value, and where are you quietly bored but staying silent?Do you want more depth, more breadth, or more control, and which environment actually supports that?What is one conversation or small action you could take this month to stop waiting and start shaping your path?

  • 43. Career Reinvention for entrepreneurial STEMM Professionals and aspiring change makers

    09:56||Ep. 43
    Reinventing STEM Careers: Unscripted Stories of Courage and Creativityif you're looking for a podcast to find your vision and make it happen, that's for you. In the inaugural 2026 episode of Multiple Hats, host Angelique Greco reintroduces the podcast dedicated to STEM professionals who seek to reshape their careers and find meaningful work. Angelique highlights her journey and the essence of the show—monthly unscripted interviews with science professionals who have engineered their careers to match their vision. Listeners gain insights into starting businesses, handling self-doubt, and redefining roles. The episode also touches on personal branding and thought leadership as crucial tools. Packed with inspiring stories of innovation and perseverance, this podcast encourages professionals to think outside the box and create their own paths.00:00 Welcome to Multiple Huts in 202600:29 What This Podcast is All About02:20 Angelique's Personal Journey04:13 The Power of Unscripted Interviews06:08 Inspiring Stories of Career Reinvention08:27 Special Series and Final Thoughts

  • 42. From Underfunded Science to Award-Winning: The Drug Discovery Rollercoaster with Dr Chris Burns

    38:43||Ep. 42
    What keeps a drug alive when the science is fragile, the funding dries up, and the company name changes four times?A 20-year survival story of near-death science, offshore funding, and final impact.🔍 What You’ll LearnIf you want a real look at how drug development and STEM careers work behind the scenes, this episode gives you the straight version, not the polished one.You’ll learn: • Why drugs are designed, not discovered, and what that means for your STEM career choices • Why starting with a strong target matters more than starting with an indication • How the financial crisis and investment landscape pushed this Australian project offshore • Why Momelotinib survived multiple handovers when it could have died at any stage • What it takes to grow from lab scientist to CEO, and the people you need around you Press play to hear the real story behind a drug that survived science hurdles, funding shocks, and corporate chaos to finally reach patients.🧠 About the GuestDr Chris Burns is the CEO and Managing Director of AmpliaTherapeutics. He is one of the few scientists who has watched a drug he helped design reach FDA approval. While he was heading Cytopia, Chris co-led the creation of Momelotinib, a JAK2 inhibitor approved for myelofibrosis in 2023 after two decades of stops, starts, handovers, and near-failures.📌 Episode Highlights00:00 Why very few scientists see their work reach patients 02:00 Designed, not discovered: the truth about drug creation 05:10 The creativity behind medicinal chemistry 08:15 How Momelotinib got its name 09:45 Preclinical wins, metabolic failures, and early near-death moments 12:00 The JAK2 discovery that shifted the entire program 15:20 Running across lily pads: designing drugs at the edge of knowledge 17:45 The metabolic wall that nearly killed the compound 20:00 Entering the clinical valley of death 21:10 The handover chain: Cytopia → YM Bioscience → Gilead → Sierra → GSK 27:00 Why Australian innovation keeps leaving the country 29:30 Practical funding advice for early biotechs 32:00 Winning the Prime Minister’s Prize 33:00 From scientist to CEO, step by step 36:00 The leadership habits that matter most🔗 Resources Mentioned• Ampio Therapeutics • Momelotinib FDA approval • Prime Minister’s Prize for Innovation • JAK2 mutation discovery • Cytopia historical research(If you want direct links added, send them through.)🤔 Reflection TimeWhich part of your own work would survive longer if you treated it like a design process instead of waiting for inspiration?What’s one area in your STEM career where timing, allies, or better funding could shift everything?If your work went through four handovers, what would keep it alive?

  • 41. Derisking Biotech: Smarter Indications and Better Resource Stretching for Early Teams

    27:28||Ep. 41
    Derisk you biotech assets with 3 key coniderations. Learn from drug development expert Angelique Greco and medtech-biotech founders and investors with tangible examples that show how real de-risking plays out. 🔍 What You’ll Learn Drug discovery feels like a maze when you're early in your career, especially when you're trying to build a biotech path without wasting years or cash. This episode gives you a clear way to turn solid science into something fundable.You’ll learn: • Where to find real support, from incubators to honest VC advice • Why early commercial input matters and how to fix your market slide • How smart entry points like animal health or adjacent indications de-risk your program and boost your funding chancesAction: Press play if you want 20 minutes that cut months of guesswork.🧠 About the Guest This episode brings insights from ShanShan Wang (RoamTech AI), Anushi Rajapaksa (Misti), Maryam Parviz (SDIP Innovations), Mike Lamprecht (Tenmile), and Ben Wright (Mimetic MedTech Foundry) on how founders can derisk and resource their team. Plus why you do not always need an indication at the start, with lessons from Dr Chris Burns, whose team discovered Momelotinib in Australia before its FDA approval.📌 Episode Highlights 00:00 Why de-risking matters for early biotech founders 00:20 Two angles: advice and smarter indication choices 01:00 How drug discovery fits a STEM entrepreneur path 01:40 Upskilling vs burning cash and time 02:10 Three pillars: compass, investors, venture studiosRoadmap & Upskilling 03:00 The value of a commercialization roadmap 03:45 Han Wang on first seeing the map 04:30 Anushi Rajapaksa on IP, regulatory and evolving the plan 06:00 Where to find training, Bridge program, NSW program 07:00 Why programs matter for network and support 08:00 Maryam Parviz on global doors opening 09:30 What you cannot Google: real conversations 10:30 How informal mentoring happens 11:00 Using tech transfer offices even if you're externalInvestor Advice 12:00 Why VC advice matters before fundraising 13:00 Mike Lamprecht on critical early experiments 14:00 What a realistic market conversation looks likeBridging Your Gaps 15:00 When to stop upskilling and bring experts 15:40 Ben Wright on scaling support instead of solo learning 16:00 How investors view founders who learn on the job 17:00 How venture studios derisk early biotech and medtech 18:00 Why structure and clinical champions matterSuccess Exists 18:45 Momelotinib as a real success story 19:10 When starting with the molecule works 20:00 Dr Chris Burns: from discovery to 2023 approvalSmarter Entry Points 22:00 Why some programs need a side door 22:30 What to check before picking an entry point 23:00 Ivermectin from livestock to humans 24:30 Ketamine and S-ketamine into severe depression 26:00 How new IP opened new paths 26:40 The semaglutide pivotFinal Takeaways 27:00 Do not do it alone 27:15 Get advice early, including from VC 27:30 Philanthropy can be a real path 27:45 Be realistic and optimistic, success exists

  • 40. What Biotech Investors Look For: The Real Checklist For Funding Your Drug or Device

    21:56||Ep. 40
    From pitch decks to de-risking strategies — how to turn promising research into an investible opportunityYou’ve got strong data and maybe even a breakthrough idea, but can you convince an investor or pharma partner that it’s worth their millions?🔍 What You’ll Learn: In this second part of the Drug Discovery Roadmap series, we move from the bench to the boardroom. If you’re a STEM researcher or biotech founder wondering what turns great science into an investible opportunity, this episode unpacks it straight from investors, pharma veterans, and researchers who’ve been through the process.You’ll learn: • How to pitch your science to investors — what to include, what to leave out, and how to get a second meeting. • Why a realistic, conservative market size matters more than billion-dollar dreams. • The smart ways to de-risk your project — from alternate indications to veterinary and agricultural applications.🎯 Play this episode to learn how to make your science fundable and credible in the eyes of those who write the cheques.🧠 About the Guests: Recorded live at the 2025 ARCS Drug Discovery Forum, this episode features insights from industry investors and researchers who’ve lived the highs and lows of drug translation:Mike Lamprecht, Investment Manager at Tenmile, on what catches his eye in a biotech pitch (and what sends red flags).Dr Wolfgang Jarolimek, Head of Drug Discovery at Syntara, on why you should never bet everything on one indication.Dr Daniel Beard, Founder and CSO of Shearflow, on how feedback from the Forum reshaped his strategy for stroke therapy.Tim Boyle, CEO of ARCS Australia, on why collaboration and “asking the right questions early” are key to commercial success.📌 Episode Highlights: 00:00 Welcome back — what makes a project investible 02:00 Tim Boyle on building the bridge between research and industry 03:45 The number one startup killer: running out of capital 04:00 Mike Lamprecht on how to pitch science to investors 06:00 Market size myths — why “$10B market” slides backfire 08:00 The antibiotic paradox: when life-saving drugs still fail commercially 10:00 Diagnostics, payers, and the hidden gap between science and buyers 11:00 Daniel Beard on differentiating his stroke therapy 14:00 How to reframe your science for clarity and investor appeal 16:00 What clinicians need to see before trials 17:00 De-risking your project: alternate indications and sectors 19:00 The case for parallel applications — human, veterinary, agriculture 20:00 Why every biotech needs backup plans 21:00 Closing takeaways: the intersection of science, strategy, and story♻️ Share this episode with researchers and biotech scientists and anyone trying to get their science to market.

  • 39. Your crashcourse in biotech commercialisation Part 1 - key considerations on the core science and adjacent considerations to take your drug to market- STEM essentials

    24:46||Ep. 39
    You’ve got strong data and maybe even a first-in-class idea, but do you know what it really takes to get your molecule from the bench to the bedside?🔍 What You’ll Learn: If you’re a STEM researcher, biotech founder, or academic thinking about commercialising your work, this episode breaks down the unseen steps between great science and a viable medicine.You’ll learn: • Why promising discoveries often fail — and how to spot the strategic blind spots early. • How to define your target product profile and use it to align experiments, reduce risk, and attract funding. • The “adjacent” essentials that make or break translation: IP timing, manufacturing readiness, and regulatory strategy.🎯 Hit play to learn what investors, regulators, and industry partners really want to see before backing your science.🧠 About the Guests: This episode features insights from the 2025 ARCS Drug Discovery Forum, where early-stage researchers pitched their projects to a panel of industry veterans and investors. You’ll hear from:Tim Boyle, CEO of ARCS Australia, on why upskilling and connection across the ecosystem are critical for success.Dr Wolfgang Jarolimek, Head of Drug Discovery at Syntara, on the importance of early pharmacokinetics and target engagement.Mike Lamprecht, Investment Manager at Tenmile, on designing “fail fast” experiments that protect capital and credibility.Dr Pegah Varamini, University of Sydney, and Dr Daniel Beard, University of Newcastle, on the real-life questions and lessons from taking lab discoveries closer to market.📌 Episode Highlights: 00:00 From promising data to the maze of translation 02:15 Tim Boyle on why ARCS bridges research and industry 05:00 Why there’s no one-size-fits-all roadmap 08:00 Why “good science” isn’t enough for commercial success 10:00 The Target Product Profile — your map from lab to market 12:30 The art of “fail fast” and defining go/no-go experiments 13:45 The non-negotiables: pharmacokinetics and target engagement 16:00 When $500M fails: the Simtuzumab story 18:00 How Pegah Varamini prepared for investor questions 21:00 The GMP vs non-GMP debate — what founders should know 23:00 Parallel priorities: IP, formulation, and manufacturing 24:00 Key takeaways and what’s next in the series🤔 Reflection Time:If you had to define your Target Product Profile today, what would your “no-go” experiment look like?Which adjacent area — IP, manufacturing, or regulatory — could derail your science if ignored too long?Who do you need in your circle to ask the right questions before it’s too late?♻️ share this episode with researcher and biotechs scientists.

  • 38. Reinventing Your STEM Career: Three Tactics I Learned from Nina Hooper That Change How You Spot Opportunities

    19:41||Ep. 38
    From student curiosity to space entrepreneurship, discover how enthusiasm, visibility, and action can unlock unexpected doors in STEM careers.Ever felt stuck in a career box, unsure how to take the next step? What if the secret wasn’t a perfect plan — but contagious enthusiasm that opens doors you didn’t know existed?🔍 What You’ll Learn:If you’re a STEM professional ready to design your own career — not just follow the one written for you — this short episode breaks down five lessons from Australian engineer and entrepreneur Nina Hooper, who built an extraordinary journey from Harvard to mining the moon.You’ll learn how to:Use enthusiasm as a catalyst to create life-changing opportunities — even without the “right” network or background.Let one step lead to the next, discovering that vision often emerges through motion, not planning.Build your own launchpad by testing ideas and learning through creation (even small projects count!).Work smarter, not harder, using AI and expert conversations to accelerate your learning and credibility.Share your story strategically, so opportunities and collaborators start finding you.🎧 Press play to discover how Nina turned curiosity into a global career — and how you can do the same starting this week.👉 Listen to the full interview with Nina Hooper for her complete story from Harvard to lunar resources:🔗 Full Episode — Multiple Hats💡 Or tune into the 5-minute Quick Fire Chat version for actionable insights you can apply today:🔗 Quick Fire Chat — Multiple Hats🧠 About the Guest:Nina Hooper is an Australian aerospace engineer and entrepreneur whose career spans Harvard, Stanford, venture capital, and her current role in business development at Interlune, a company developing technology to mine the moon for future energy resources. Passionate about creating opportunity through enthusiasm and initiative, Nina embodies how STEM professionals can design a career that’s anything but linear.📌 Episode Highlights:00:00 — From curiosity to career: Why enthusiasm is gold03:00 — How a cold outreach led to an internship with a Nobel Prize winner07:00 — Vision emerges in motion: Why you don’t need the perfect plan10:00 — Creating your own vision through entrepreneurship during COVID13:00 — What running an ed-tech startup teaches you about sales, mindset & confidence15:00 — Working smarter with AI and mentors18:00 — The art of visibility: Why storytelling matters as much as hard work19:00 — Reflection prompts for your own reinvention journey🔗 Resources Mentioned:Interlune – https://interlune.space🤔 Reflection Time:How can you make your enthusiasm more visible this week so others feel compelled to help you?What’s one small step you can take — without waiting for a perfect plan — to move toward your next opportunity?How might you use AI or expert conversations to fill a skill gap faster and smarter?

  • 37. STEM Career Myths: The Sneaky Beliefs That Stall Your Progress with Nina Hooper

    11:56||Ep. 37
    Which career myth is secretly holding you back: thinking hard work is enough, that skills don’t transfer, or that your work will speak for itself?🔍 What You’ll Learn:In just 10 minutes, Nina Hooper, astrophysicist turned entrepreneur and now business development director at Interlune, shows you how to reframe the beliefs that limit most STEM professionals. If you’re ready to stop playing small and start shaping your own career, this quickfire chat delivers clarity and motivation fast.Why your technical skills transfer further than you think — and which ones transfer best.How working smarter (and asking for help) beats grinding harder every time.Why visibility and storytelling matter more than letting your work “speak for itself.”How to move past perfectionism, analysis paralysis, and the myth that you need “all the resources” before you can start.🎯 Press play for a mindset reset that could open your next big opportunity in STEM.🧠 About the Guest:Nina Hooper is an Australian aerospace engineer turned entrepreneur and investor. She has studied at Harvard and Stanford, launched startups, worked in venture capital, and is now Director of Business Development at Interlune, a company pioneering lunar resource extraction.📌 Episode Highlights:00:00 Busting STEM career myths in 10 minutes01:00 Why technical skills transfer beyond academia03:00 Working smarter vs. working harder05:00 Getting past analysis paralysis and perfectionism07:00 Do you really need more resources to start?09:00 Why visibility matters more than “great work alone”🔗 Resources Mentioned:Nina Hooper on LinkedInInterlune – Lunar Resources Company🤔 Reflection Time:Which STEM career myth do you secretly believe — and what would shift if you dropped it?Where could you work smarter by asking for help or using tools instead of grinding harder?Who could you share your vision with this month to increase your visibility and attract new opportunities?

  • 36. STEM Career Pivot: How Nina Hooper Turned Curiosity into Career-Defining Moves from Harvard to Space Tech

    57:38||Ep. 36
    What if your enthusiasm—not your credentials—was the spark that could turn your STEM career into a launchpad of endless opportunities?🔍 What You’ll Learn:If you’re a STEM professional who feels boxed in, Nina Hooper’s story shows how you can turn your own spark of curiosity into life-defining opportunities. From interning with a Nobel Prize winner to Harvard and Stanford, launching startups, and now helping build a company mining the moon, Nina reveals how to reinvent your career by standing out, stepping out, and showing up.Why enthusiasm is your unfair advantage: how showing up with energy makes you memorable and opens doors credentials alone can’t.How stepping out of your comfort zone to test your vision—even briefly—can accelerate your corporate or entrepreneurial career.Why visibility and connections matter more than great work alone, and how to use them to attract opportunities.Bonus Learning: How the future of energy may be powered by helium-3 and other resources extracted from the moon, with insights from Nina’s work at Interlune.🎯 Press play to learn how to make your STEM background the launchpad for entrepreneurship, visibility, and influence.🧠 About the Guest:Nina Hooper is an Australian aerospace engineer turned entrepreneur and investor. From interning with Nobel Prize winner Brian Schmidt to studying at Harvard and Stanford, launching her own ventures, and working in venture capital, she’s now Director of Business Development at Interlune, a company pioneering lunar resource extraction. Nina is passionate about helping others see curiosity as a career driver and visibility as a catalyst for influence.📌 Episode Highlights:00:00 Curiosity as the spark for aerospace engineeringThe promise of helium-3 and the future of lunar energy resources04:15 How a Nobel Prize connection changed Nina’s trajectory08:30 Why enthusiasm makes you stand out in STEM13:45 From Harvard to NASA: chasing vision over comfort zones20:10 Selling ideas with energy and conviction25:50 Lessons from founding a STEM education startup32:00 Flipping the script: moving into venture capital37:45 Working smarter, not harder in STEM careers42:00 Why visibility and storytelling matter more than great work alone🔗 Resources Mentioned:Brian Schmidt – Nobel Prize in PhysicsNina Hooper on LinkedInHarvard–Smithsonian Center for AstrophysicsInterlune – Lunar Resources Company🤔 Reflection Time:How could enthusiasm and energy make you stand out in your current STEM role?What’s one step outside your comfort zone you could take to begin shaping your own vision?Who could you connect with this month to increase your visibility and open new doors?